Non-Invasive. AI-Powered. Clinically Validated.
NeuroDx by OncoSieve is the first saliva and dried blood spot (DBS)-based microfluidic platform specifically designed to differentiate Parkinson’s Disease (PD), Multiple System Atrophy (MSA), and Progressive Supranuclear Palsy (PSP) using a validated biomarker-AI pipeline.
Key System Features
Key System Features– 
AI-Based Classifier: Trained on over 2,000 cases, including SMOTE-augmented PSP data.
– 
Biomarker Detection: pS129/α-synuclein and NfL measured with <10 pg/mL sensitivity.
– 
ROC-AUC Performance: 0.93 (95% CI: 0.91–0.96) for PSP vs. PD/MSA.
– 
Light-Induced Fluorescence Optics: 45° oblique LIF chamber with mirror coating.
– 
Synthetic Control Integration: AviTag-spiked α-synuclein recovery validation.
Technology & IP
Technology & IP– Patent-pending platform with multiple claims on optical system, spike-in controls, and multi-marker AI.
– Performance validated via:
– Antibody clone substitution protocols
– Lot-to-lot reproducibility
– Stability simulation under ambient conditions
Clinical & Commercial Potential
Clinical & Commercial Potential– 
Early PSP detection where misdiagnosis delays are common
– Suitable for home use, clinical trials, and neurology labs
– Enhances stratification in biomarker-linked trials (e.g., α-syn targeting)